Enliven Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Enliven Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-7.7%
Buyback Yield
Total Shareholder Yield | -7.7% |
Future Dividend Yield | n/a |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ELVN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ELVN's dividend payments have been increasing.
Dividend Yield vs Market
Enliven Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (ELVN) | n/a |
Market Bottom 25% (US) | 1.3% |
Market Top 25% (US) | 4.2% |
Industry Average (Pharmaceuticals) | 2.4% |
Analyst forecast (ELVN) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate ELVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ELVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ELVN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ELVN has not reported any payouts.